Could an Alzheimer's Drug Be Approved Monday?

By: ETFdb
Biotechnology sector-related exchange traded funds are in for a wild ride as Biogen (NasdaqGS: BIIB) is set to receive a verdict from the Food and Drug Administration on its Alzheimer’s drug.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.